Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...
Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition
JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.
Hosted on MSN2mon
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal
Johnson & Johnson agreed to acquire mental-illness ... Bristol-Myers in 2023 struck a deal to pay $14 billion for Karuna Therapeutics, whose schizophrenia drug Cobenfy is expected to generate ...